Long-term of Remote Ischemic Preconditioning in Patients With Mild Hypertension

Not Applicable

• Conditions: Hypertension

• Registration Number: NCT04753840
• Lead Sponsor: Henan Institute of Cardiovascular Epidemiology

Brief Summary

According to the latest survey data of China hypertension annual meeting, there are about 300 million patients with hypertension in China, with 10 million new cases of hypertension each year, and there is an obvious trend of younger people. In particular, young and middle-aged people are in a state of mild hypertension for a long time, which causes great pressure on health and medical treatment. At present, the main clinical measures for mild hypertension are to change their eating habits, quit smoking and alcohol, exercise and other lifestyle changes, as well as drug control. For most patients with mild hypertension, drug control is not the best choice. It has been reported that remote ischemic preconditioning (RIPC) may play an effective role in reducing blood pressure .The purpose of this study was to investigate the extent of long-term application of RIPC to reduce blood pressure in patients with mild hypertension.

Detailed Description

A total of 200 patients with mild hypertension were enrolled in this study, using the method of open label and parallel grouping; 100 cases in the experimental group and 100 cases in the control group, The experimental group was divided into life intervention + drug group and life intervention + ripc group, with 50 patients in each group. The results of 24-hour ambulatory blood pressure monitoring (ABPM) of the three groups were observed before and 3 months after use, including HR, pulse pressure, 24-hour systolic blood pressure, 24-hour diastolic blood pressure, daytime systolic blood pressure, daytime diastolic blood pressure, nighttime systolic blood pressure and nighttime diastolic blood pressure. The changes of renalase, catecholamine, renin, angiotensin - Ⅱ, aldosterone, RhoA kinase, no, adenosine and bradykinin were observed.

Study Timeline

• Study First Submitted: 2021-02-10
• Study First Submitted QC: 2021-02-10
• Study First Posted: 2021-02-15
• Study Start: 2021-07-03
• Status Verified: 2022-08
• Last Update Submitted: 2022-08-03
• Last Update Posted: 2022-08-05
• Primary Completion: 2023-02-20
• Study Completion: 2023-02-20

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

• Diagnosed patients with mild hypertension (SBP: 140~159mmHg; DBP: 90~99mmHg)

Exclusion Criteria

• Cannot tolerate RIPC
• Non-essential hypertension
• patients who have uncontrolled severe arrhythmia, diabetes, electrolyte disturbance
• patients who have severe organic diseases such acute myocardial infarction, cardiac insufficiency, abnormal renal function, etc.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Mean diastolic blood pressure	3 months	24-hour Mean diastolic blood pressure measured by Ambulatory blood pressure monitoring
Mean systolic blood pressure	3 months	24-hour Mean systolic blood pressure measured by Ambulatory blood pressure monitoring

Secondary Outcome Measures

Name	Time	Method
Concentration of Renalase	3 months	blood renalase concentration
Concentration of adenosine	3 months	blood adenosine concentration
Concentration of renin	3 months	blood renin concentration
Concentration of catecholamine	3 months	Blood catecholamine concentration
Concentration of bradykinin	3 months	blood bradykinin concentration

Trial Locations

Locations (1)

Fuwai central China Cardiovascular hospital; 🇨🇳 Zhengzhou, Henan, China